Sponsors (8)
The bill tightens federal restrictions and liability around mifepristone—reducing availability for abortion and clarifying legal limits while expanding private legal remedies—creating a trade‑off between restricting access and increasing civil accountability that will raise costs, legal uncertainty, and care barriers for many patients and providers.
Clinicians and hospitals: receive clearer federal limits on prescribing or using mifepristone for pregnancy termination, reducing regulatory ambiguity about that specific use.
People who claim injury from mifepristone: gain an explicit private right to sue manufacturers and recover compensatory and punitive damages plus attorney fees, improving access to civil remedies.
Injured individuals: can still pursue additional or broader relief under State law because the bill preserves state-law remedies alongside the federal causes of action.
Pregnant people seeking medication abortion: will lose or face substantially reduced access to an FDA‑approved medication (mifepristone) for early abortion, creating a major barrier to reproductive care.
Patients who need medication abortion or medical management of miscarriage: will likely face delayed care, increased travel, higher out-of-pocket costs, or the need for more invasive surgical procedures.
Manufacturers, distributors, and pharmacies: face increased criminal and civil liability risk for interstate distribution of mifepristone, which could raise prices, reduce supply, or prompt withdrawal from U.S. markets.
Based on analysis of 8 sections of legislative text.
Declares FDA approval for mifepristone for pregnancy termination withdrawn, bans interstate commerce for that use, and creates a federal private right of action against manufacturers.
Official title: Provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Introduced March 11, 2026 by Joshua David Hawley · Last progress March 11, 2026
Deems FDA approvals for mifepristone for termination of intrauterine pregnancy to be withdrawn shortly after enactment, makes introduction or delivery of that drug for that indication into interstate commerce a federal violation, and treats labeling that claims use for termination as misbranding. It also creates a federal private right of action against manufacturers of mifepristone for bodily injury or mental-health harms allegedly caused by the drug, authorizing compensatory and punitive damages and attorneys’ fees, with state-law remedies preserved. The statutory withdrawal and commerce restrictions take effect 14 days after enactment; the private right of action becomes effective 90 days after enactment.